Terminated PHASE2 INTERVENTIONAL 4-arm NCT01182350

Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)

Phase II Trial of Molecularly Determined Treatment of Children and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas

Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago

Conditions Diffuse Intrinsic Pontine Glioma

Interventions Bevacizumab Erlotinib Radiation Temozolomide

Updated 15 times since 2017 Last updated: Aug 13, 2019 Started: Sep 30, 2011 Primary completion: Jun 30, 2016 Completion: Jun 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Per design: Stop if fewer than 3 cohorts by molecular classification were with 10 participants or only 1 cohort enrolled at least 15 participants of 50.

Other terminated trials from Ann & Robert H Lurie Children's Hospital of Chicago

See all terminations from Ann & Robert H Lurie Children's Hospital of Chicago

Listed as NCT01182350, this PHASE2 trial focuses on Diffuse Intrinsic Pontine Glioma and remains terminated or withdrawn. Sponsored by Ann & Robert H Lurie Children's Hospital of Chicago, it has been updated 15 times since 2011, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

15 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE2

▶ Show 10 earlier versions

Nov 2020 — Jan 2021 [monthly]

Terminated PHASE2
Sep 2020 — Nov 2020 [monthly]

Terminated PHASE2
Mar 2020 — Sep 2020 [monthly]

Terminated PHASE2
Oct 2019 — Mar 2020 [monthly]

Terminated PHASE2

Status: Completed → Terminated
Aug 2018 — Oct 2019 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Jun 2018 — Aug 2018 [monthly]

Active Not Recruiting PHASE2
May 2018 — Jun 2018 [monthly]

Active Not Recruiting PHASE2
Aug 2017 — May 2018 [monthly]

Active Not Recruiting PHASE2
Feb 2017 — Aug 2017 [monthly]

Active Not Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE2

First recorded

Sep 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ann & Robert H Lurie Children's Hospital of Chicago
Boston Children's Hospital
Children's Healthcare of Atlanta
Children's Hospital Colorado
Children's Hospital Los Angeles
Children's Hospital of Michigan
Children's Hospitals and Clinics of Minnesota
Children's National Research Institute
Cook Children's Medical Center
Duke University
Johns Hopkins University
Karen D. Wright MD
Lucile Packard Children's Hospital
Medical University of South Carolina
Milton S. Hershey Medical Center
Nemours Children's Clinic
New York University
Nicklaus Children's Hospital f/k/a Miami Children's Hospital
OHSU Doernbecher Children's Hospital
Phoenix Children's Hospital
Seattle Children's Hospital
University of California, San Francisco
University of Louisville
Washington University School of Medicine

Data source: Dana-Farber Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Aurora, United States , Baltimore, United States , Boston, United States , Charleston, United States , Chicago, United States , Dallas, United States , Detroit, United States , Durham, United States , Fort Worth, United States and 13 more locations